# | Title | Journal | Year | Citations |
---|
1 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families | Journal of Clinical Oncology | 2020 | 270 |
2 | Genomic landscape and chronological reconstruction of driver events in multiple myeloma | Nature Communications | 2019 | 183 |
3 | Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse | Blood | 2018 | 172 |
4 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups | Leukemia | 2018 | 137 |
5 | Timing the initiation of multiple myeloma | Nature Communications | 2020 | 99 |
6 | Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). | Journal of Clinical Oncology | 2020 | 86 |
7 | Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial | Journal of Clinical Oncology | 2023 | 76 |
8 | Wilms tumour | Nature Reviews Disease Primers | 2021 | 75 |
9 | Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial | Annals of Oncology | 2019 | 65 |
10 | Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database | Lancet Oncology, The | 2018 | 59 |
11 | Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA | Journal of Molecular Diagnostics | 2018 | 45 |
12 | Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases | Clinical Cancer Research | 2021 | 35 |
13 | Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. | Journal of Clinical Oncology | 2020 | 33 |
14 | Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology | Mutation Research - Reviews in Mutation Research | 2018 | 32 |
15 | Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer | Journal of Cellular Physiology | 2019 | 31 |
16 | Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review | Cancers | 2020 | 29 |
17 | Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials | Cancer Medicine | 2020 | 29 |
18 | Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature | Cancers | 2021 | 27 |
19 | Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure | Cells | 2020 | 26 |
20 | Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience | Cancer and Metastasis Reviews | 2019 | 22 |
21 | Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer | Cancers | 2019 | 22 |
22 | One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis | Oncologist | 2019 | 21 |
23 | Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data | Oncologist | 2021 | 20 |
24 | SARS‐CoV‐2 disease and children under treatment for cancer | Pediatric Blood and Cancer | 2020 | 19 |
25 | Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults | Expert Review of Clinical Pharmacology | 2019 | 18 |
26 | Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting | European Journal of Cancer | 2021 | 18 |
27 | <i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Haematologica | 2021 | 18 |
28 | Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells | MAbs | 2018 | 17 |
29 | Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus | European Journal of Cancer | 2022 | 17 |
30 | Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria | European Journal of Cancer | 2022 | 16 |
31 | Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma | HemaSphere | 2020 | 15 |
32 | ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy | ESMO Open | 2020 | 15 |
33 | O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001) | Annals of Oncology | 2020 | 14 |
34 | Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP) | Annals of Oncology | 2021 | 14 |
35 | Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer | Cancers | 2020 | 13 |
36 | Sport activities and exercise as part of routine cancer care in children and adolescents | Pediatric Blood and Cancer | 2019 | 12 |
37 | DICER1-associated malignancies mimicking germ cell neoplasms: Report of two cases and review of the literature | Pathology Research and Practice | 2021 | 12 |
38 | Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction | Frontiers in Oncology | 2018 | 11 |
39 | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment | Cellular Oncology (Dordrecht) | 2019 | 11 |
40 | Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients | | 2021 | 11 |
41 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants | Genetics in Medicine | 2022 | 10 |
42 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups | Leukemia | 2017 | 9 |
43 | Risk‐reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice? | Psycho-Oncology | 2019 | 9 |
44 | O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma | Annals of Oncology | 2020 | 9 |
45 | Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse | Cancer Gene Therapy | 2021 | 9 |
46 | Positive Impact of Organized Physical Exercise on Quality of Life and Fatigue in Children and Adolescents With Cancer | Frontiers in Pediatrics | 2021 | 9 |
47 | BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer | Cellular Oncology (Dordrecht) | 2022 | 9 |
48 | Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody | Cells | 2020 | 8 |
49 | Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy | Cancers | 2021 | 8 |
50 | Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only − the SIOP 93–01 and 2001 protocols | European Journal of Cancer | 2022 | 8 |